All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke with Giovanna Lucchini, Great Ormond Street Hospital, London, UK. We asked, How does graft-versus-host disease (GvHD) affect outcomes for pediatric patients undergoing allogeneic stem cell transplantation (allo-SCT) for acute lymphoblastic leukemia (ALL)?
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
Lucchini begins by describing how background disorders impact GvHD in patients post transplant. Lucchini then discusses the concept of engineering GvHD that is 'enough, but not too much' and highlights the need for more strategies to support patients and control GvHD.
Findings from the prospective iMAGINE trial of ibrutinib in pediatric patients with chronic GvHD
Chronic graft-versus-host disease (cGvHD) is a significant cause of mortality and morbidity after allogeneic hematopoietic stem cell transplantation...
When would you use ATG vs PTCy for GvHD prophylaxis?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked,...
Subscribe to get the best content related to GvHD delivered to your inbox